Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 1/20 | 0.40 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406457 | 0.84 | PIM1 (0.46) | VNN1PIM1MAPTSMN1; SMN2TP53 | |
| SCHEMBL5404686 | 0.80 | PIM1 (0.46) | VNN1PIM1MAPTSMN1; SMN2TP53 | |
| SCHEMBL6204014 | 0.75 | RUNX1 (0.40) | SMN1; SMN2MEN1KMT2AL3MBTL1RUNX1 | |
| SCHEMBL5417862 | 0.73 | CRHR1 (0.49) | VNN1PIM1MAPTSMN1; SMN2TP53 | |
| SCHEMBL5423317 | 0.71 | CRHR1 (0.56) | VNN1PIM1MAPTSMN1; SMN2TP53 | |
| SCHEMBL5406545 | 0.70 | CRHR1 (0.70) | VNN1MAPTSMN1; SMN2TP53MEN1 | |
| SCHEMBL14416671 | 0.69 | CLK1 (0.46) | MAPTSMN1; SMN2PDE5AMEN1KMT2A | |
| SCHEMBL6203416 | 0.69 | RUNX1 (0.40) | SMN1; SMN2MEN1KMT2ARUNX1 | |
| SCHEMBL31289746 | 0.68 | VNN1 (0.46) | VNN1MAPTTP53POLBCCNE2 | |
| SCHEMBL5420376 | 0.68 | CRHR1 (0.43) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-7179807-B2 | 5-substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-6995161-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1255740-B1 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050215559-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
| EP-1554258-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1500653-A1 | Substituted arylpyrazines | Neurogen Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2004018437-A1 | 5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20030018035-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2003-01-23 | — | — | US | disclosed |
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | VNN1 2406/4885PIM1 3669/4885MAPT 1407/4885 |
| US-20040106620-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | VNN1 2221/4885PIM1 4615/4885MAPT 2932/4885 |
| US-20050215559-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | VNN1 2406/4885PIM1 3669/4885MAPT 1407/4885 |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | VNN1 2221/4885PIM1 4615/4885MAPT 2932/4885 |
| US-20030018035-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | VNN1 2512/4885PIM1 3919/4885MAPT 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.